Almirall stock holds above 52-week low as analysts see upside

Published on 09/18/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock closed at EUR 10.62 on the Spanish Mercado Continuo on September 17, 2026, only modestly above its 52-week low near EUR 10.02. Recent analyst commentary with a EUR 16.00 price target highlights upside potential if fundamentals stabilize.

Dermatologe untersucht Patientenrücken mit Dermatoskop vor Barcelona-Skyline — Almirall S.A. (ES0157097017) zeigt Dermatologie-Praxis mit Hautuntersuchung und unbeschrifteten Cremetuben in Barcelona, Illustration mit AI erstellt.

Almirall stock (ISIN ES0157097017) finished the September 17, 2026 session at EUR 10.62 on the Spanish Mercado Continuo, leaving the shares only modestly above a 52-week low near EUR 10.02 and underscoring the cautious mood around the Barcelona-based pharmaceutical group.

Analyst upside contrasts with subdued price

According to Ad-hoc-news on September 18, 2026, Almirall stock closed at EUR 10.62 on September 17, 2026 on the Spanish Mercado Continuo, slipping about 0.6 percent from the prior session around EUR 10.68 as the IBEX 35 benchmark gained roughly 1 percent to finish near 19,832 points.

This places Almirall only slightly above a 52-week low reported near EUR 10.02, so the current share price stands less than EUR 1.00 above the bottom of the recent range while remaining far below a EUR 16.00 analyst price target reiterated in mid-September 2026, highlighting a visible gap between market pricing and analyst expectations.Ad-hoc-news

Recent results frame the risk-reward

While the latest detailed interim figures are not contained in this week's search results, investors generally look to Almirall's most recent half-year and quarterly reports to gauge whether its dermatology and specialty care portfolio can support a turnaround in earnings and justify the upside implied by a EUR 16.00 price target.

Historical context from prior reporting periods suggests that revenue growth and margin trends in core prescription segments are central to the investment case, with adjustments for R&D and licensing income often determining whether net profit expands faster than sales.

Stock underperforms Spanish benchmark

As noted by Ad-hoc-news, Almirall's 0.6 percent decline on September 17, 2026 contrasted with an approximately 1 percent gain in the IBEX 35 to around 19,831.8 points, meaning the stock lagged the Spanish blue-chip index by more than 1.5 percentage points on that trading day.

For investors, this short-term underperformance adds to a picture in which the stock trades close to its 52-week low, even as selected analyst commentary continues to point to higher levels around EUR 16.00 as a fair value estimate, implying potential upside of roughly 50 percent from the September 17, 2026 closing price if such targets were eventually reached.

Price level and trading venue

At the close of trading on September 17, 2026, Almirall stock was quoted at EUR 10.62 on the Spanish Mercado Continuo, the company's primary listing venue, with the shares near the lower end of their 52-week range and underperforming the IBEX 35 on the same day.